These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 3125787)

  • 1. Emergence of resistance to imipenem in Pseudomonas aeruginosa.
    Lynch MJ; Drusano GL; Mobley HL
    Antimicrob Agents Chemother; 1987 Dec; 31(12):1892-6. PubMed ID: 3125787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of imipenem resistance acquired by three Pseudomonas aeruginosa strains during imipenem therapy.
    Vurma-Rapp U; Kayser FH; Hadorn K; Wiederkehr F
    Eur J Clin Microbiol Infect Dis; 1990 Aug; 9(8):580-7. PubMed ID: 2120059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections.
    Quinn JP; Dudek EJ; DiVincenzo CA; Lucks DA; Lerner SA
    J Infect Dis; 1986 Aug; 154(2):289-94. PubMed ID: 3088133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imipenem resistance in clinical isolates of Proteus mirabilis associated with alterations in penicillin-binding proteins.
    Neuwirth C; Siébor E; Duez JM; Péchinot A; Kazmierczak A
    J Antimicrob Chemother; 1995 Aug; 36(2):335-42. PubMed ID: 8522463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of resistance to beta-lactam antibiotics in Pseudomonas aeruginosa during treatment with new beta-lactams.
    Lerner SA; Quinn JP
    Chemioterapia; 1985 Feb; 4(1):95-101. PubMed ID: 3921267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imipenem resistance in Acinetobacter baumanii is due to altered penicillin-binding proteins.
    Gehrlein M; Leying H; Cullmann W; Wendt S; Opferkuch W
    Chemotherapy; 1991; 37(6):405-12. PubMed ID: 1760939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffusion of meropenem and imipenem through the outer membrane of Escherichia coli K-12 and correlation with their antibacterial activities.
    Cornaglia G; Guan L; Fontana R; Satta G
    Antimicrob Agents Chemother; 1992 Sep; 36(9):1902-8. PubMed ID: 1416880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mechanism of susceptibility and resistance of bacteria to beta-lactam antibiotics].
    Tsuji A
    Nihon Rinsho; 1991 Oct; 49(10):2254-60. PubMed ID: 1749080
    [No Abstract]   [Full Text] [Related]  

  • 9. Association of two resistance mechanisms in a clinical isolate of Enterobacter cloacae with high-level resistance to imipenem.
    Lee EH; Nicolas MH; Kitzis MD; Pialoux G; Collatz E; Gutmann L
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1093-8. PubMed ID: 1929248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular basis of the non-beta-lactamase-mediated resistance to beta-lactam antibiotics in strains of Haemophilus influenzae isolated in Canada.
    Clairoux N; Picard M; Brochu A; Rousseau N; Gourde P; Beauchamp D; Parr TR; Bergeron MG; Malouin F
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1504-13. PubMed ID: 1510447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of the in vitro spectrum of activity of imipenem.
    Jones RN
    Am J Med; 1985 Jun; 78(6A):22-32. PubMed ID: 3890537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel resistance to imipenem associated with an altered PBP-4 in a Pseudomonas aeruginosa clinical isolate.
    Bellido F; Veuthey C; Blaser J; Bauernfeind A; Pechère JC
    J Antimicrob Chemother; 1990 Jan; 25(1):57-68. PubMed ID: 2108115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro and in-vivo antibacterial activity of imipenem against clinical isolates of bacteria.
    Mitsuhashi S
    J Antimicrob Chemother; 1983 Dec; 12 Suppl D():53-64. PubMed ID: 6607914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-lactam resistant Pseudomonas aeruginosa strains emerging during therapy: synergistic resistance mechanisms.
    Pagani L; Debiaggi M; Tenni R; Cereda PM; Landini P; Romero E
    Microbiologica; 1988 Jan; 11(1):47-53. PubMed ID: 2832709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of carbapenem BMS-181139 against Pseudomonas aeruginosa is not dependent on porin protein D2.
    Fung-Tomc JC; Gradelski E; Kolek B; Minassian B; Pucci M; Kessler RE; Bonner DP
    Antimicrob Agents Chemother; 1995 Feb; 39(2):386-93. PubMed ID: 7726503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical characterization of novel tetrahydrofuranyl 1beta-methylcarbapenems: stability to hydrolysis by renal dehydropeptidases and bacterial beta-lactamases, binding to penicillin binding proteins, and permeability properties.
    Yang Y; Testa RT; Bhachech N; Rasmussen BA; Bush K
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2904-9. PubMed ID: 10582880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms by which imipenem may overcome resistance in gram-negative bacilli.
    Williams RJ; Yang YJ; Livermore DM
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():9-13. PubMed ID: 3493237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent activity of meropenem against Escherichia coli arising from its simultaneous binding to penicillin-binding proteins 2 and 3.
    Sumita Y; Fukasawa M
    J Antimicrob Chemother; 1995 Jul; 36(1):53-64. PubMed ID: 8537284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by beta-lactamases.
    Yang Y; Bhachech N; Bush K
    J Antimicrob Chemother; 1995 Jan; 35(1):75-84. PubMed ID: 7768785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired imipenem uptake associated with alterations in outer membrane proteins and lipopolysaccharides in imipenem-resistant Shigella dysenteriae.
    Ghosh AS; Kar AK; Kundu M
    J Antimicrob Chemother; 1999 Feb; 43(2):195-201. PubMed ID: 11252324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.